Compare the benefits and risks associated with new systemic agents for the treatment of castrate resistant prostate cancer (CRPC) including immunotherapy, secondary hormonal agents, chemotherapy, and radiopharmaceuticals.
Assess current treatment guidelines regarding appropriate sequencing of new therapeutic approaches for the treatment of CRPC.
Appraise individual patient disease characteristics: recognize, understand, and manage disease and treatment related complications associated with CRPC.
Formulate appropriate care plans and provide counsel for patients and their families.
You must be logged in and own this session in order to